Diagnostic Testing of Iron Homeostasis & Metabolism
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - G2011 alerts
Get alerted when Policy AHS - G2011 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coverage limits for laboratory testing of iron status (serum ferritin, transferrin saturation, hepcidin, GlycA) for Medical Mutual - Ohio members; applies to providers ordering iron-related laboratory tests.
CC1: added '(no more than one test per month unless otherwise specified)'.
CC1b: clarified and added a frequency: 'Once every three weeks for individuals with an iron overload disorder.'
CC1.h: edited to include CKD-dependent frequencies: one test every three months if not on dialysis; one test every month if receiving dialysis.
New CC1.j: added coverage for individuals with restless legs syndrome or periodic limb movement disorder.
New CC2.d: added coverage for individuals with restless legs syndrome or periodic limb movement disorder.
Note 1 updated to align symptoms of hemochromatosis with Cleveland Clinic and expanded to include arrhythmias, erectile dysfunction, knuckle pain, and more specific abdominal pain location.
CC1a edited for clarity.
Coverage Criteria for Iron-related Laboratory Testing
inv-01: Serum ferritin — Covered indications
Measurement of serum ferritin levels (no more than one test per month unless otherwise specified) MEETS COVERAGE CRITERIA when any of the following are present:
No more than one test per month unless otherwise specified
Exception to general monthly cap for iron overload
Frequency specified per KDIGO-aligned revision
Newly added to covered indications
inv-02: Transferrin saturation — Covered indications
Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA when any of the following are present:
Use TSAT <20% as supportive of iron deficiency per guideline contexts
AASM recommends TSAT and ferritin testing in clinically significant RLS
inv-05: Revised coverage criteria and frequency rules
Measurement of serum ferritin or transferrin (including transferrin saturation) for indications not explicitly listed in the policy does not meet coverage criteria and may be denied. The policy states that ferritin measurement meets coverage criteria when performed no more than one test per month unless otherwise specified, with specified exceptions (for example, iron overload and CKD frequencies) and explicit covered indications such as anemia, hemochromatosis evaluation, first‑degree relatives of confirmed hereditary hemochromatosis, liver disease evaluation, HLH/Still Disease, secondary hypogonadism in males, individuals on iron therapy, and restless legs syndrome/perioric limb movement disorder.
Published guidance and the policy record that no established guidelines support using ferritin as a first‑line test in asymptomatic individuals. The policy therefore does not endorse routine ferritin screening of asymptomatic people and requires clinical indication aligned with the listed covered situations for coverage.
The United States Preventive Services Task Force (USPSTF) has concluded that evidence is insufficient (Grade I) to recommend routine screening for iron deficiency anemia in asymptomatic pregnant individuals and in children aged 6–24 months. The policy references this determination when advising that routine asymptomatic screening in these populations is not supported by sufficient evidence.
This revision cycle focused on adding explicit frequency limits and new covered indications rather than introducing new test exclusions. The Revision History documents the operational frequency caps (e.g., no more than one test per month unless otherwise specified, and specific exceptions such as once every three weeks for iron overload), plus the addition of restless legs syndrome as a covered indication.
Serum hepcidin testing, including immunoassays, is explicitly stated in the policy as DOES NOT MEET COVERAGE CRITERIA. The policy cites lack of sufficient published scientific literature supporting clinical utility as the rationale for noncoverage.
Measurement of ferritin as a routine first‑line screening test in asymptomatic individuals is not supported by identified published recommendations. The policy therefore limits coverage to defined clinical indications and frequency rules rather than permitting indiscriminate screening.
USPSTF findings that current evidence is insufficient to recommend routine screening for iron deficiency anemia in asymptomatic pregnant individuals and children aged 6–24 months are cited by the policy. These determinations inform the policy stance that routine asymptomatic screening in pregnancy and young children is not supported by sufficient evidence and coverage is determined by documented clinical indication.
Ordering tests more frequently than the policy allows (for example, exceeding one ferritin test per month where no exception applies) may be considered not medically necessary and is subject to denial. The Revision History and frequency rules emphasize adherence to the specified intervals (monthly cap, once every three weeks for iron overload, quarterly or monthly for CKD depending on dialysis status).
Covered Indications and Clinical Uses
Testing Frequency Limits and Monitoring Intervals
Procedure and Diagnostic Codes
| 82728 | Ferritin |
| 83540 | Iron |
| 83550 | Iron binding capacity |
| 84466 | Transferrin |
| 84999 | Unlisted chemistry procedure |
| 0024U | Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (proprietary test: GlycA Lab/Manufacturer: Laboratory Corporation of America) |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma (proprietary test: Intrinsic Hepcidin IDx™) |
Provider Actions, Documentation, and Authorization Notes
No blanket prior authorization
This policy contains no explicit prior authorization (PA) requirement for ferritin, transferrin/TSAT, or related iron studies; coverage is governed by the indications and frequency limits in the policy rather than a blanket PA rule.
IV iron authorization requires oral-trial / absorption documentation
IV iron is recommended when oral iron is not tolerated, ferritin does not improve after an oral iron trial, or when absorption is likely impaired; documentation of the prior oral trial or of conditions limiting absorption may be required to authorize IV iron.
Procedure codes listed (reference only)
Procedure codes for ferritin and iron studies are provided for reference; the document does not impose prior authorization tied to these CPT/HCPCS codes.
Follow frequency and indication rules rather than expecting blanket PA
There is no blanket prior authorization; instead follow the policy's operational requirements for covered indications and specified frequency limits when requesting coverage.
Oral-first approach before IV iron
Whenever possible, attempt an every‑other‑day oral iron regimen as first‑line therapy because it is often better tolerated and absorbed; IV iron is reserved for intolerance, lack of response after an oral trial, or impaired absorption.
- Every-other-day oral iron may be better tolerated and has similar absorption compared to daily dosing.
- Use IV iron if oral iron is not tolerated, ferritin does not improve after an oral trial, or absorption is likely impaired.
Therapy sequencing: oral → assess → consider IV
Treat iron deficiency with oral iron as first‑line therapy and monitor response per guideline recommendations; escalate to IV iron only per the oral‑first approach and documented clinical need.
- Oral iron is first-line; monitor hemoglobin/ferritin response and reassess before proceeding to IV therapy.
Benefit verification required
Verify the member's current benefit coverage at the time of the request and apply the policy's coverage criteria and frequency limits to the individual's benefits.
Laboratory and clinical documentation to support orders
Document relevant laboratory and clinical data when ordering iron studies: include ferritin, TSAT (transferrin saturation), and inflammatory markers (e.g., CRP) where inflammation or CKD may affect ferritin interpretation; record prior treatments and response to oral or IV iron.
- Document ferritin and TSAT whenever interpretation may be confounded by inflammation or CKD (consider CRP).
- Record prior oral iron trial and documented response when IV iron is considered.
Monitoring documentation: serial CBC and ferritin per guidance
Monitor therapeutic response with serial CBC and ferritin measurements; recheck ferritin 3–6 months after normalization or after initiation of supplementation and follow CKD-specific monitoring cadence (every 3 months if not on dialysis; monthly if on dialysis).
- Recheck ferritin 3–6 months after normalization or after starting supplementation.
- For CKD patients: test hemoglobin, ferritin, and TSAT every 3 months if not on dialysis, monthly if on hemodialysis.
Support orders with indication and frequency documentation
Include documentation that supports the specific covered indication and adheres to the policy's frequency limits (e.g., iron overload, CKD dialysis status, restless legs syndrome) when ordering tests to avoid denials.
- Specify the indication category (iron overload disorder, CKD with/without dialysis, RLS, anemia, etc.) in the order.
- Ensure testing interval requested matches frequency limits in policy (monthly, quarterly, or every 3 weeks as specified).
Risk of denial for tests outside listed indications
Ordering ferritin, transferrin, or TSAT for indications not listed in the policy does not meet coverage criteria and may be denied; ensure the clinical indication aligns with the policy's covered situations before ordering.
- Tests outside listed indications (including routine screening in asymptomatic individuals) are not covered per the policy.
Hemochromatosis workup required to avoid missed diagnosis
When evaluating abnormal liver chemistries for possible hereditary hemochromatosis, perform iron level, transferrin saturation, and serum ferritin as recommended; failure to perform these tests risks missing a diagnosis and may lead to clinical/coverage issues.
- ACG recommends testing iron, TSAT, and serum ferritin in patients with abnormal liver chemistries in the absence of acute hepatitis.
Government policies take precedence
If state or federal government policy (LCD/NCD/Medicaid) conflicts with this policy, the applicable government policy takes precedence and will be used to make coverage determinations.
Denial risk for frequency noncompliance
Ordering tests more frequently than the policy permits (e.g., exceeding one ferritin test per month where not otherwise allowed, or more frequent than specified for iron overload or CKD) may trigger denial as not medically necessary.
- General cap: no more than one serum ferritin test per month unless a subcriterion specifies a different frequency.
- Exceptions: once every three weeks for iron overload; CKD: quarterly if not on dialysis, monthly if on dialysis.
Ordering Requirements and Recommended Test Panels
Verify benefits; no provider-type restriction listed
Coverage is dependent on the individual's benefit coverage at time of request; the policy does not impose a specific provider-type ordering restriction in this section.
Order tests per specialty society guidance
Order ferritin, serum iron, and TSAT in clinical contexts following specialty society guidance (AGA, ACG, ASCO/ASH, AAFP, WHO); for example, evaluate for hemochromatosis when abnormal liver chemistries are present.
- Follow AGA/ACG recommendations for contexts such as anemia and abnormal liver chemistries.
Order set for anemia evaluation (CBC + iron studies)
When evaluating anemia, include a core order set of CBC, serum ferritin, serum iron, TIBC, and calculate TSAT; in inflammatory states consider reticulocyte hemoglobin content or hepcidin if available.
- Core tests: CBC, ferritin, serum iron, TIBC, TSAT.
- Consider RET‑He or hepcidin in inflammatory states when available.
Document clinical indication and frequency on orders
The order must document the clinical indication that aligns with the coverage criteria and must adhere to specified frequency limits to be considered covered.
- Include the covered indication on the laboratory order.
- Confirm requested test timing meets policy frequency limits.
Tests and Uses Not Covered
The policy lists tests that are not covered: serum hepcidin testing (including immunoassays) and GlycA testing to measure or monitor transferrin or other glycosylated proteins do not meet coverage criteria. The GlycA analytic limitations (inability to accurately quantify individual protein concentrations) are cited as part of the rationale for noncoverage.
GlycA is not an appropriate substitute for specific protein measurements such as transferrin because the GlycA NMR signal represents a composite of glycoprotein signals and cannot accurately determine individual protein concentrations. For that reason the policy states GlycA testing does not meet coverage criteria for measuring transferrin or other glycosylated proteins.
The policy considers routine screening for iron deficiency anemia in asymptomatic pregnant people and children ages 6–24 months to have insufficient evidence for benefit, consistent with USPSTF Grade I findings; such routine screening is therefore not supported as a covered service in this policy.
Within the updated policy window no additional specific tests were added to an explicit exclusion list; instead, the revisions primarily modify testing frequencies and add clinical indications (for example, restless legs syndrome) while restating that hepcidin and GlycA are not covered.
Definitions and Biomarker Descriptions
Background and Clinical Context
Iron homeostasis involves intestinal absorption, transport by transferrin, cellular uptake via transferrin receptors, and storage in ferritin. Hepcidin is the central regulatory peptide that binds ferroportin and decreases iron export from cells; serum ferritin largely reflects body iron stores but is also an acute‑phase reactant and can be elevated in inflammation, liver disease, or malignancy, which may confound interpretation. Transferrin saturation (TSAT) is calculated from serum iron and total iron‑binding capacity and complements ferritin when assessing iron availability and distinguishing deficiency from inflammatory elevation of ferritin.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.